Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
47.73%
Operating Margin
22.59%
Net Margin
11.69%
Efficiency Metrics
Revenue per Expense Ratio
1.29
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
26.16%
Income Tax Rate
13.01%
EPS
6.2300000000
Balance Sheet Analysis
Current Ratio
0.78
Cash Ratio
0.39
Working Capital
$-102.67M
Debt to Equity
1,585,713,000.0
Debt to Assets
91.12%
Equity Ratio
-14.42%
Cash Flow Analysis
Operating Cash Flow Ratio
15.78%
Free Cash Flow Ratio
11.31%
CapEx to Revenue
4.47%
Dividends Paid
$31.72M
Stock Buybacks
$26.13M
Total Shareholder Returns
$57.85M
Cash Position Change
-41.32%
Key Takeaways (2023 FY)
Revenue declined by 8.6137923602543%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.42%
Detailed Growth Metrics
Core Performance
Revenue
-8.61%
Net Income
19.81%
EPS
25.35%
Operating Income
6.62%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
3.83%
Operating Cash Flow
46.79%
Free Cash Flow
73.96%
Balance Sheet Health
Assets
-7.50%
Debt
-7.49%
Book Value per Share
13.14%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
7.42%
Shares Outstanding
-4.03%
Long Term Trends
3Y Revenue/Share
28.46%
5Y Revenue/Share
22.49%
3Y Dividend/Share
41.18%
5Y Dividend/Share
-28.60%